Author of

• 11866

  +

  P2.18 - Poster Session 2 - Pathology (ID 176)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Pathology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 11872

    +

    P2.18-006 - HER2 and BRAF mutations in non-small-cell lung cancer (NSCLC) patients (p). (ID 1243)

    09:30 - 09:30  |  Author(s): A. Indacochea
    • Abstract

    Background
    Treatment of non-small-cell lung cancer (NSCLC) has changed drastically in recent years with an increase in rates of detection of driver mutations in a subgroup of NSCLC patients (p); the most recent mutations described in NSCLC are HER2 and BRAF. Overexpression of HER-2 (insertion in exon 20) occurs in 2-6% of NSCLC patients and is more common in women, never-smokers, Asian and adenocarcinoma hystology (adc). BRAF is found in 1.6-4.9% of p, with a higher rate of V600E mutations in smokers, and non-V600E mutations in non-smokers.

    Methods
    We systematically analyzed HER2 and BRAF mutations in EGFR wild type and non-translocated ALK p and retrospectively reviewed the results. Forty six NSCLC p were included between December 2011 to June 2013. Clinical characteristics such as histological subtype, sex, age, smoking status, and mutational status were analyzed. BRAF mutation was assessed by Taqman based assay (5’ nuclease activity) in an AB 7900HT system, with specific primers and probes for V600E positions. HER2 insertion was assessed using Sanger sequencing. All samples were PCR amplified and sequenced in AB 3130, using specific primers for exon 20.

    Results
    All patients were Caucasian; 25 p (54.3%) were women and 21 p (45.7%) men. Fourteen p (30.4%) were never-smokers, 11 (23.9%) former smokers and 19 (41.3%) smokers. Median age was 58.74 years. Forty one p (89.1%) had adc, 2 had squamous cell histology and 3 had another histology (1carcinod tumour, 1 large cell lung cancer and 1 poorly differentiated NSCLC) . Two p (4.3%) had BRAF V600E mutation: 1 female and 1 male, with median age of 56.5, both smokers. One 65 year old, female, never-smoker p (2.2%) had HER-2 insertion. All mutations were found in adc.

    Conclusion
    Analysis of less common driver mutations such as BRAF and Her2 mutations is feasible for daily clinical practice and could be useful to decide treatment. In our European population, incidence of BRAF and HER-2 mutation is similar to that previously reported (4.3% and 2.2%). Both p with BRAF V600E mutation were smokers, and the p with mutation in HER-2 was a 65 year-old female never-smoker.